Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Study: Medical Marijuana Reduces Pain, Depression, Increases Life Quality in
Cancer Patients
https://www.newsmax.com/health/health-news/cancer-marijuana-medical-pain/2022/05/24/id/1071322
HAPPY BIRTHDAY PRESIDENT DONALD J TRUMP FROM CHARLIE WARD & ALL OF THE TRUTH COMMUNITY
WATCH
https://www.bitchute.com/video/VztdCmvZLgU/
CT Thanks; How many more good music artists has been hit like Justin Bieber???
DR. JUDY MIKOVITS PhD - THE PLAN TO INJECT HUMANITY WITH CANCER VIRUSES!
WATCH
https://www.bitchute.com/video/QMT4KXNWow9c/
Justin Bieber recently came out to tell fans he’s come down with Ramsay Hunt
Syndrome, which caused partial paralysis in his face — it turns out RHS is a
known vaccine side effect.
https://thecountersignal.com/justin-bieber-paralysis-is-a-known-vaccine-side-effect/
STATEMENT BY PRESIDENT DONALD J. TRUMP
Quote:
could not copy the entire story-- here is the link
:
https://cdn.nucleusfiles.com/e7/e746fae9-7a5f-462d-a0dd-dd9a11895451/statement-by-president-donald-j.-trump.pdf?
M_P; $500 TRILLION LAWSUIT AGAINST THE FEDERAL GOVT AND OVER 140
MONOPOLISTS (REMOVED BY YOUTUBE IN 5HRS)
WATCH
https://www.bitchute.com/video/QFcfDjifRl6u/
Leaked medicare data shows a 50% rise in all cause mortality of the elderly for the first time ever.
https://www.bitchute.com/video/DdxZLSGHmKLB/
They are right. Covid kills...the Covid vaccine is killing the elderly by the thousands. Source: Fat News.
CLIF HIGH - THE JABBED ARE ABOUT TO GET A RUDE AWAKENING
https://www.bitchute.com/video/bBcmJoO3BRdh/
"Organoids "Jab victim discharging biological creatures woman reports horror after Moderna shot
https://www.bitchute.com/video/BCrvrznQFaME/
SUBMIT TO THE BIOWEAPON OR REMAIN OUR HOSTAGE FOREVER --
BRENT JOHNSON - NWO Totalitarian Dictators Blackmail Anti-Human Genocide
killer agenda super communistic evil khazarian
WATCH
https://www.bitchute.com/video/l881ILlbk6UJ/
BREAKING!!! COVID VACCINE CLAIMS OVERWHELM COURTS
WATCH
https://www.bitchute.com/video/fxqw0Y7twx3o/
MASS DEPOPULATION ACCORDING TO PFIZER! - DOCUMENT LEAK
PROVES VACCINE IS CAUSING DIE OFF!
WATCH
https://www.bitchute.com/video/Ga7fvxiL1jFa/
Zardiw; Sarah Palin Pulls Ahead In Race For Alaska Representative
Photo of Carmine Sabia Carmine SabiaJune 12, 2022
https://conservativebrief.com/sarah-p-63700/
CT; M_P; VACCINES ARE MAKING PEOPLE NEUROLOGICALLY NUMB
WATCH
https://www.bitchute.com/video/aT3AxrAOGWeT/
US Is "Beyond Bankrupt" - Kim Dotcom Fears "Controlled Demolition" Enabling A "New Dystopian Future"
Tyler Durden's Photo
BY TYLER DURDEN
SATURDAY, JUN 11, 2022 - 04:44 AM
https://www.zerohedge.com/markets/its-worse-many-can-imagine-kim-dotcom-sees-controlled-demolition-enabling-new-dystopian
https://rumble.com/v1896jo-real-love.html
https://www.whatdoesitmean.com/index.htm
God Bless.
Ps.
Bill Holter – A Parallel Economy Is Emerging Which Wreak Havoc On The [CB]
System - X22 Report - VIDEO
https://x22report.com/aiovg_videos/bill-holter-a-parallel-economy-is-emerging-which-wreak-havoc-on-the-cb-system/
Jan. 6 Was ‘An Inside Job to Entrap People Who Attended Trump’s Speech’:
Investigative Journalist.. :+O
https://www.theepochtimes.com/jan-6-was-an-inside-job-to-entrap-people-who-attended-trumps-speech-investigative-journalist_4524391.html
MediPharm Labs Strengthens Recreational Business Adding Flower and Pre-Rolls to Portfolio - Acquires IP from Canadian Consumer Favourite, Shelter Cannabis Brands
• Known for its high-quality, specialty recreational dried flower products, Shelter Cannabis is expected to complement MediPharm's existing Canadian cannabis portfolio.
• Adds IP and well-regarded Shelter brands Wildlife and Shelter Craft to MediPharm.
• MediPharm expects to leverage its recently expanded national sales network to drive Shelter's growth beyond current five province market.
• MediPharm will produce Shelter Cannabis products in its Barrie, Ontario facility, enhancing capacity utilization which leverages existing infrastructure and overhead.
• This new position in the Canadian flower market creates opportunity to improve MediPharm's existing medical cannabis flower distribution network, where products are already shipped to pharmaceutical partners in Germany and the UK.
• Expected increased activity and success in the Canadian adult use market continues to support MediPharm resources needed to maintain leadership as a global pharmaceutical company specialized in cannabis.
• Non-dilutive, with 100% performance-based cash payment.
TORONTO, March 22, 2022 /CNW/ - MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced that it has acquired the intellectual property portfolio of Shelter Cannabis ("Shelter"), including cannabis dried flower and pre-roll products, manufacturing know-how, trademarks, marketing assets and provincial listings (the "Transaction"). MediPharm will pay Shelter based on an earn-out reflective of future gross sales, net of excise tax. MediPharm-originated shipments are expected to begin during Q2 2022.
Transaction Highlights
• Fills a key gap in MediPharm product portfolio – MediPharm strengthens its recreational business by adding Shelter's highly recognizable Wildlife and Craft dried flower and pre-roll brands and products; dried flower is a roughly CAD $2.6B category that accounts for over 70 per cent of domestic cannabis sales1. The addition of these brands and products aligns with the Company's portfolio of pharmaceutical cannabinoid products to create a differentiated business focused on quality and craftsmanship in cannabis.
• Investments made to date create frictionless pathways to integrate and optimize Shelter Cannabis brands – With its established provincial agreements, logistics and sales teams, the Company will aim to optimize investments made to date and solidify its presence in the Canadian adult-use market. Over the past eight months, MediPharm has added considerable resources to its established sales network across Canada – which is now composed of over 20 dedicated sales and marketing professionals. MediPharm sees an opportunity to leverage this network to deepen Shelter's shelf presence in its existing provinces, and to expand to additional markets. MediPharm now ships to 9 of the 10 provinces with Newfoundland registration underway.
• Additional synergies by moving Shelter's production to MediPharm's existing facility – Shelter's brands are currently being produced at a facility in Saskatchewan. MediPharm will move production to its existing facility in Barrie, Ontario with very little capital expenditure required, enhancing capital utilization of facilities and staff, and driving additional margin.
• Opportunity to expand international medical flower business – MediPharm already supplies medical flower to the UK and German medical cannabis markets where flower makes up the majority of sales.
• Non-dilutive transaction, with payment based on future performance – MediPharm has arranged to pay the vendor a royalty solely based on the future Shelter Cannabis sales, making the transaction cost 100 per cent performance based. This is expected to minimize risk to MediPharm shareholders, while maximizing return and allows MediPharm to retain its substantial cash position for future growth opportunities.
Management Commentary
Bryan Howcroft, CEO of MediPharm commented, "This Transaction represents an important step as MediPharm continues to focus on building a Canadian recreational portfolio that is relevant, profitable and grounded in the Company's unwavering commitment to high quality products. With Shelter, we see a significant opportunity to get a head start in the important dried flower and pre-roll segment of the market, with the addition of a well-regarded list of brands, led by Shelter's flagship Wildlife brand. With MediPharm's existing buying power, and established sales and production platforms, we believe there are multiple opportunities to generate revenue and cost synergies through this Transaction, to continue building value for MediPharm shareholders. Expected increased activity and success in the Canadian adult use market supports MediPharm resources as we continue to build out our pharmaceutical business with traditional pharma customers being part of longer development and sales cycle."
Shelter's CEO Michael Nederhoff said, "We are very excited by the opportunity that MediPharm has created for our brands to live on in the Canadian recreational market. After a successful journey, Shelter and Wildlife have made a lasting impression which MediPharm will now take ownership of and continue to grow."
About MediPharm Labs
Founded in 2015, MediPharm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
In 2021, MediPharm received a Pharmaceutical Drug Establishment Licence from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing Licence for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: new position in Canadian flower market and creation of opportunity to improve MediPharm's medical cannabis flower distribution network; expected increased activity and success in the Canadian adult use market; growth of the Shelter brands beyond their current market; enhanced capacity utilization of Shelter products in the Barrie facility; when shipments will commence, ability to create a differentiated business focused, opportunity to leverage its established sales network to deepen Shelter's shelf presence; capital expenditure required; enhanced utilization; additional margins being driven; and minimized risk to MediPharm shareholders while maximizing return. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
1 MJBiz – 2021 annualized figures based on January to June 2021 Canadian sales data
For further information: MediPharm Labs Investor Relations, Telephone: +1 416.913.7425 ext. 1525, Email: investors@medipharmlabs.com, Website: www.medipharmlabs.com
MJBiz – 2021 annualized figures based on January to June 2021 Canadian sales data
Cision View original content to download
multimedia:
https://www.prnewswire.com/news-releases/medipharm-labs-strengthens-recreational-business-adding-flower-and-pre-rolls-to-portfolio--acquires-ip-from-canadian-consumer-favourite-shelter-cannabis-brands-301507309.html
SOURCE MediPharm Labs Corp.
MediPharm Labs Signs Committed Term Sheet for $20 Million Debt Facility With Schedule 1 Bank
past 2 days I have had a "buy" order in that was above the "ask" and it did not go through. Who is manipulating this stock??
MediPharm Labs Signs New Cannabis Oil Agreements and Completes First Shipments of Supply in December
TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS; OTCQB: MLCPF) (the “Company” or “MediPharm Labs”), the leader in specialized, research-driven cannabis extraction, fully licensed under the Cannabis Act (Canada) focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification, is pleased to announce it has signed three cannabis oil sales agreements, subsequent to the Company’s receipt of its sales license from Health Canada on November 9, 2018. The first large shipments of cannabis oil supply left the Company’s dock in December 2018 and were aggregately valued at over $10 million.
“As a pioneer in the cannabis industry, MediPharm Labs has emerged as the clear leader in the extraction-only category, highlighted by our first month of sales agreements of white label high-quality purified cannabis oil concentrates,” said Mr. Patrick McCutcheon, Chairman, President and Chief Executive Officer of MediPharm Labs. “This milestone further validates the strength of our differentiated model as a complement and partner to vertically integrated licensed producers while also demonstrating the potential for MediPharm to rank alongside the top revenue generating cannabis companies in the industry.”
“Looking ahead to 2019, we continue to build on our momentum as MediPharm is increasingly being recognized as the supplier of choice for high-quality purified cannabis oil as well as for toll processing, particularly among mid-to-large-sized vertically integrated licensed producers, and we see a clear path for continued and sustainable growth in 2019 and beyond. We look forward to further accelerating growth through the multitude of substantial contracts already in place and robust pipeline of new opportunities, which will be further enhanced in the near future upon receiving full cGMP producer certification and opening up additional international opportunities.”
MediPharm Labs’ strong momentum has continued into 2019 with several significant accomplishments to support its continued growth as the leader in specialized, research-driven cannabis extraction business designed for large scale commercial production. Highlights include:
Processed and sold large quantities of cannabis oil inventory under its white label program. Has since acquired large volume of dried cannabis to ensure uninterrupted supply of oil for existing and new customers. Deep industry relationships and proactive supply chain management have secured over 1,600kg of cannabis flower and trim over a 3-week period from 7 different licensed producers (“LPs”). The Company has now made supply purchases from 13 LPs and is continuing to procure additional supply to meet strong demand.
Executed multiple long-term tolling agreements with 6 LPs under Cannabis Concentrates Program under which it has received large quantities of dried cannabis for processing. In addition to the current arrangements in place, the Company has a robust pipeline of new opportunities which are under evaluation and/or negotiation.
Initial extraction capacity of 100,000 kg of dried cannabis was increased by 50% to an industry leading capacity of 150,000 kg as approved by Health Canada December 24, 2018. (This total capacity equates to 29.1 million vape pen cartridges equivalent). Continued expansion plans are underway to support growing demand for cannabis oils, the fastest growing segment of the cannabis industry.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from its cGMP (current Good Manufacturing Practices) and ISO standard-built clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products. MediPharm Labs was awarded Start-Up Of The Year at the recent Canadian Cannabis Awards hosted by Lift & Co.
Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.
For further information, please contact:
Laura Lepore, Vice President, Investor Relations & Communications
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, expectations for uninterrupted cannabis oil supply for existing and new customers, future expansion plans and capacities, expected GMP certification and the establishment of operations in Australia. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; and the delay or failure to receive regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
https://web.tmxmoney.com/article.php?newsid=4618643803671563&qm_symbol=LABS
We hanging out mlcpf board fyi
Speaking of snoozing...U.S. buyers are missing out. :)
You snooze you loose. Ready to see this ticker get chased. Seat belt's buckled, let's gooo $LABS/MLCPF
Let’s go labs choo choo
Yeah buddy I’m super long on medi only 6 million shares in float. Amazing management, basically no debt, and they are profitable
Nice correction today let’s keep going tomorrow !!! 2019 labs $5*+
Tweed ceo says extraction companies are a good buy !!
Power house in the making , sad part is they ipo right when markets crash ... this is a major international company in making imho
serously bummed here, because I cant buy down today being that the US Market is closed. ugggg
Huge shakeout. Watch this baby bounce back even more!
$LABS.V
Nice volume today ..keep making them deals !!
Canopy Growth Completes Strategic Extract Supply Agreement With MediPharm Labs
https://www.newswire.ca/news-releases/canopy-growth-completes-strategic-extract-supply-agreement-with-medipharm-labs-701540301.html?fbclid=IwAR0oLXBL5clJxRTtOQ5jX71d8r3BplFGi4d2VTheZ_K5KKU0k30VgeDM7Qg
Now that they have their sales license, I’d think that we’ll be seeing plenty of agreements finalized in the coming weeks/months.
Supreme Cannabis Partners with MediPharm Labs to Enter Cannabis Oil Products Market https://www.newcannabisventures.com/supreme-cannabis-partners-with-medipharm-labs-to-enter-cannabis-oil-products-market/
MediPharm Labs Corp. Receives Sales Licence from Health Canada https://www.newcannabisventures.com/medipharm-labs-corp-receives-sales-licence-from-health-canada/
This baby is about to run to close the week! Loaded up on shares!!
$LABS.V
Looking good
Added 1.85, 1.55 , 1.35 American side :)
Should be great once seller is done !!
Small SS and international soon!
Same here. This stock is so undervalued its nuts!!
when did it come off the Grey market. Why did it go Grey right when it started?
Anyone on the board here I’m buying the shit out of stock
it opened as a Grey. Today is the 1st day MLCPF has traded. Don't sweat it man.
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
73
|
Created
|
09/27/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |